Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Chiu PY et al. – Based on the results of this study, rivastigmine administered usually at a dose of 3–6 mg twice daily was found to be well tolerated. Although the rate of adverse events was high, the majority of these symptoms were mild in severity and short in duration. This study also demonstrated the efficacy of rivastigmine in at least stabilizing the symptoms of Alzheimer's disease.

Related Articles

Does Diabetes Speed Up Memory Loss In Alzheimers Disease?
ScienceDaily, 10/28/09    Relevance Score: 70%

High Blood Pressure Likely in Alzheimers Offspring
MedLinePlus, 11/04/09    Relevance Score: 69%

Protective Role For Copper In Alzheimers Disease
ScienceDaily, 10/14/09    Relevance Score: 68%

More Iowans fight Alzheimer's
Internet Source, 11/17/09    Relevance Score: 67%

Obesity and Alzheimers Disease: A Link Between Body Weight and Cognitive Function in Old Age
American Journal of Alzheimer's Disease and Other Dementias, 10/07/09    Relevance Score: 67%

Today in Neuro/Psych pharmacology...keeping you current

Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid
Multiple Sclerosis, 12/11/09

Behavioral Dimensions and Acetylcholinesterase Inhibitor-related Effect in Alzheimer Disease Over Time: A Latent Trajectory Modeling
Cognitive and Behavioral Neurology, 12/11/09

Depression in Parkinson's Disease
Canadian Journal of Neurological Sciences, 12/10/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address